GSK is a large pharma headquartered in UK. Over the past three years, GSK has been involved in 54 licensing and acquisition transactions, with a primary focus on Small Molecules (11 deals). The company currently has 5 active clinical trials, primarily in Infectious Disease.
Deals (12mo)
7
Active Trials
5
Top Modality
Small Molecules
Focus Area
Infectious Disease
Licensing, acquisition, and partnership transactions involving GSK in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| EOS-448 (belrestotug) | iTeos | Antibodies | Phase 2 | co development | Jun 25, 2026 |
| Nuvalent precision kinase inhibitor portfolio | Nuvalent | Small Molecules | Unknown | acquisition | Jun 9, 2026 |
| HRS-9821 | Jiangsu Hengrui | Small Molecules | Unknown | option | Jun 3, 2026 |
| siRNA obesity program | Siran Biotechnology | Oligonucleotides | Preclinical | acquisition | May 23, 2026 |
| JNJ-3989 | Arrowhead | Oligonucleotides | Unknown | license | Apr 1, 2026 |
| JNJ-3989 | Arrowhead Pharmaceuticals | Other | Unknown | license | Mar 28, 2026 |
| JNJ-3989 | Arrowhead Pharmaceuticals | Oligonucleotides | Unknown | license | Mar 27, 2026 |
| mRNA vaccines for influenza | CureVac | mRNA | Unknown | collaboration | Mar 24, 2026 |
| JNJ-3989 | Arrowhead/Janssen | Other | Unknown | acquisition | Mar 23, 2026 |
| linerixibat | Alfasigma | Small Molecules | Phase 3 | license | Mar 10, 2026 |
Showing 10 of 19 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where GSK is most active based on deal history and clinical trial data.
Key indicators of GSK's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
GSK has 5 active clinical trials across 3 development phases.
2
Phase 1
1
Phase 2
2
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
GSK is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 54 deals over the past three years, GSK ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK include Infectious Disease (23 deals and trials), Oncology (22 deals and trials), Codev Deals (8 deals and trials), and Option Deals (7 deals and trials). In terms of modality, GSK has shown particular interest in small molecules, oligonucleotides, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against GSK's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals